The full set of scientific papers supporting this hypothesis, visualized
as a force-directed graph. Each gray node is one paper; hover for the
extracted claim, click to open it on PubMed.
Building network…
Figure 2. Evidence network for ketamine → NMDA receptor → pain.
Each gray node represents a scientific paper from the Robertium extraction.
A→B edges show ketamine → NMDA receptor claims; B→C edges show NMDA receptor → pain claims.
Hover for details, click a paper to open PubMed.
Sparse evidence — 9 papers total. See Limitations section for context.View as text list
A→B papers (8)
PMID 41765199 — Ketamine pharmacotherapy for major depressive disorder: A narrative review (2026) · mechanism of action conf 0.95
PMID 41656677 — Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials (2026) · general conf 0.90
PMID 41690063 — Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience (2026) · general conf 0.95
PMID 35783539 — Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions (2022) · mechanism of action conf 0.95
PMID 32209965 — Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives (2020) · sub-anesthetic doses conf 0.95
PMID 31579184 — Efficacy of ketamine therapy in the treatment of depression (2019) · in vitro conf 0.90
PMID 31617335 — Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment‐resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans (2019) · in vitro or in vivo (general) conf 0.95
PMID 29722313 — Ketamine enhances structural plasticity in human dopaminergic neurons: possible relevance for treatment-resistant depression (2018) · as non-competitive antagonist conf 0.90
B→C papers (1)
PMID 33467407 — Delayed Onset Muscle Soreness (DOMS): The Repeated Bout Effect and Chemotherapy-Induced Axonopathy May Help Explain the Dying-Back Mechanism in Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases (2021) · in DOMS and ALS according to gate control theory conf 0.60
Full audit trail of how this hypothesis was generated: source papers,
extracted claims, bridging logic, embedding model, and scoring. Every
step is recorded and reproducible.
Provenance trace not available for hypothesis 5385.
Limited evidence base in our current extraction. Treat this hypothesis as a
starting point for further literature review, not a settled conclusion.
A → B evidence:
ketamineinhibitsNMDA receptor
PMID 41765199Ketamine pharmacotherapy for major depressive disorder: A narrative review(2026)
PMID 41656677Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials(2026)
PMID 41690063Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience(2026)
PMID 35783539Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions(2022)
PMID 32209965Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives(2020)
PMID 31579184Efficacy of ketamine therapy in the treatment of depression(2019)
PMID 31617335Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment‐resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans(2019)
PMID 29722313Ketamine enhances structural plasticity in human dopaminergic neurons: possible relevance for treatment-resistant depression(2018)
B → C evidence:
NMDA receptorassociated withpain
PMID 33467407Delayed Onset Muscle Soreness (DOMS): The Repeated Bout Effect and Chemotherapy-Induced Axonopathy May Help Explain the Dying-Back Mechanism in Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases(2021)
References
All PMID-linked papers cited in the evidence network above, deduplicated and sorted by
publication year.
PMID 41765199 Ketamine pharmacotherapy for major depressive disorder: A narrative review(2026)A→B
PMID 41656677 Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials(2026)A→B
PMID 41690063 Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience(2026)A→B
PMID 35783539 Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions(2022)A→B
PMID 33467407 Delayed Onset Muscle Soreness (DOMS): The Repeated Bout Effect and Chemotherapy-Induced Axonopathy May Help Explain the Dying-Back Mechanism in Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases(2021)B→C
PMID 32209965 Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives(2020)A→B
PMID 31579184 Efficacy of ketamine therapy in the treatment of depression(2019)A→B
PMID 31617335 Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment‐resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans(2019)A→B
PMID 29722313 Ketamine enhances structural plasticity in human dopaminergic neurons: possible relevance for treatment-resistant depression(2018)A→B
Limitations & disclaimer
This hypothesis was generated algorithmically through cross-domain literature analysis and has not been experimentally validated. Treat it as a starting point for further investigation, not a therapeutic recommendation. For established knowledge about each entity, refer to the authoritative sources linked above (Wikipedia, DrugBank, UniProt, MeSH).
Related hypotheses
Other hypotheses in the catalog sharing the same drug or mediator.